What happens next in GLP-1 — and when.

Get the briefing

What moved in the GLP‑1 field, in your inbox.

@glp1briefing

Sponsors › Boehringer Ingelheim

Boehringer Ingelheim

Every GLP‑1 and incretin trial, approval and scheduled result we hold for Boehringer Ingelheim, drawn from ClinicalTrials.gov and Drugs@FDA.

Boehringer Ingelheim is a commercial sponsor with 12 trials in the incretin class on file here, across 2 molecules. The programme is split between 3 early-stage trials and 9 in phase 3 or later. No approved FDA submission is recorded against this sponsor for these molecules, which is normal for a programme that has not reached the market. The next scheduled result is 2028-01-17.

Molecules
semaglutide · survodutide
Trials on file
12
Active trials
3
Results scheduled
1
Approved FDA submissions
0

Results due

Est. completionDrugTrialPhaseParticipants
2028-01-17survodutideA Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461
P3600

Trials on file

All 12 incretin trials recorded for this sponsor, active first.

DrugTrialStatusPhaseParticipants
survodutideLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444
RecruitingP31,800
survodutideLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457
RecruitingP31,590
survodutideA Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461
RecruitingP3600
survodutideA Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864
CompletedP35,531
survodutideA Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
NCT06066528
CompletedP3755
survodutideA Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
NCT06066515
CompletedP3726
semaglutideA Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
NCT04153929
CompletedP2413
survodutideA Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
NCT04667377
CompletedP2387
survodutideA Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
NCT06214741
CompletedP3307
survodutideA Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
NCT04771273
CompletedP2295
survodutideA Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease
NCT06176365
CompletedP3274
survodutideA Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
NCT06309992
CompletedP3218